Drug Patents owned by Ocular Therapeutix

1. Drug name - DEXTENZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9254267 OCULAR THERAPEUTIX Composite hydrogel drug delivery systems Sep, 2024

(1 year, 11 months from now)

US8563027 OCULAR THERAPEUTIX Drug delivery through hydrogel plugs Feb, 2030

(7 years from now)

US8409606 OCULAR THERAPEUTIX Drug delivery through hydrogel plugs May, 2030

(7 years from now)

Drugs and Companies using DEXAMETHASONE ingredient

Treatment: Dextenza is approved for the treatment of ocular pain following ophthalmic surgery


More Information on Dosage
Strength Dosage Availability

availability in other generic markets.

Click on the highlighted region to filter.